Development of next-generation respiratory virus vaccines through targeted modifications to viral immunomodulatory genes

Expert Review of Vaccines

Volumn 14, Issue 12, 2015, Pages 1563-1572

  Stobart, Christopher C ^a,b   Moore, Martin L ^a,b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CHILDREN'S HEALTHCARE OF ATLANTA   (United States)

Author keywords

Coronavirus; Immunology; Influenza; Measles; Mumps; Next generation vaccines; Pathogenesis; Respiratory syncytial virus; Respiratory viruses

Indexed keywords

RESPIRATORY SYNCYTIAL VIRUS VACCINE; LIVE VACCINE; SUBUNIT VACCINE; VIRUS VACCINE;

CORONAVIRIDAE; HUMAN; HUMAN RESPIRATORY SYNCYTIAL VIRUS; INFLUENZA; INFLUENZA VIRUS; MEASLES; MEASLES VIRUS; MUMPS; MUMPS VIRUS; PRIORITY JOURNAL; REVIEW; VACCINATION; VIRUS GENE; CORONAVIRUS INFECTIONS; GENETICS; IMMUNOLOGY; INFLUENZA, HUMAN; ORTHOMYXOVIRIDAE; RESPIRATORY TRACT INFECTIONS; VIROLOGY;

CORONAVIRUS; CORONAVIRUS INFECTIONS; HUMANS; INFLUENZA, HUMAN; MEASLES; MEASLES VIRUS; MUMPS; MUMPS VIRUS; ORTHOMYXOVIRIDAE; RESPIRATORY SYNCYTIAL VIRUSES; RESPIRATORY TRACT INFECTIONS; VACCINES, ATTENUATED; VACCINES, SUBUNIT; VIRAL VACCINES;

EID: 84947048041     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.2015.1095096     Document Type: Review

References (128)

1. Morens DM, Fauci AS. The 1918 influenza pandemic: insights for the 21st century. J Infect Dis 2007;195:1018-28
2. Szewczyk B, Bienkowska-Szewczyk K, Krol E. Introduction to molecular biology of influenza a viruses. Acta Biochim Pol 2014;61:397-401
3. Dash P, Thomas PG. Host detection and the stealthy phenotype in influenza virus infection. Curr Top Microbiol Immunol 2015;386:121-47
4. Wise HM, Foeglein A, Sun J, et al. A complicated message: Identification of a novel PB1-related protein translated from influenza A virus segment 2 mRNA. J Virol 2009;83:8021-31
5. Chen W, Calvo PA, Malide D, et al. A novel influenza A virus mitochondrial protein that induces cell death. Nat Med 2001;7:1306-12
6. Jagger BW, Wise HM, Kash JC, et al. An overlapping protein-coding region in influenza A virus segment 3 modulates the host response. Science 2012;337:199-204
7. Muramoto Y, Noda T, Kawakami E, et al. Identification of novel influenza A virus proteins translated from PA mRNA. J Virol 2013;87:2455-62
8. Wolff T, O'Neill RE, Palese P. NS1-Binding protein (NS1-BP): a novel human protein that interacts with the influenza A virus nonstructural NS1 protein is relocalized in the nuclei of infected cells. J Virol 1998;72:7170-80
9. O'Neill RE, Talon J, Palese P. The influenza virus NEP (NS2 protein) mediates the nuclear export of viral ribonucleoproteins. EMBO J 1998;17: 288-96
10. Plotch SJ, Bouloy M, Ulmanen I, Krug RM. A unique cap(m7GpppXm)-dependent influenza virion endonuclease cleaves capped RNAs to generate the primers that initiate viral RNA transcription. Cell 1981;23: 847-58
11. Dias A, Bouvier D, Crepin T, et al. The cap-snatching endonuclease of influenza virus polymerase resides in the PA subunit. Nature 2009;458:914-18
12. Ichinohe T, Pang IK, Iwasaki A. Influenza virus activates inflammasomes via its intracellular M2 ion channel. Nat Immunol 2010;11:404-10
13. Pinto LH, Lamb RA. Controlling influenza virus replication by inhibiting its proton channel. Mol Biosyst 2007;3:18-23
14. Pinto LH, Lamb RA. The M2 proton channels of influenza A and B viruses. J Biol Chem 2006;281:8997-9000
15. Talon J, Horvath CM, Polley R, et al. Activation of interferon regulatory factor 3 is inhibited by the influenza A virus NS1 protein. J Virol 2000;74:7989-96
16. Guo Z, Chen LM, Zeng H, et al. NS1 protein of influenza A virus inhibits the function of intracytoplasmic pathogen sensor, RIG-I. Am J Respir Cell Mol Biol 2007;36:263-9
17. Mibayashi M, Martinez-Sobrido L, et al. Inhibition of retinoic acid-inducible gene I-mediated induction of beta interferon by the NS1 protein of influenza A virus. J Virol 2007;81:514-24
18. Gack MU, Albrecht RA, Urano T, et al. Influenza A virus NS1 targets the ubiquitin ligase TRIM25 to evade recognition by the host viral RNA sensor RIG-I. Cell Host Microbe 2009;5:439-49
19. Wang X, Li M, Zheng H, et al. Influenza A virus NS1 protein prevents activation of NF-kappaB and induction of alpha/beta interferon. J Virol 2000;74:11566-73
20. Ludwig S, Wang X, Ehrhardt C, et al. The influenza A virus NS1 protein inhibits activation of Jun N-terminal kinase and AP-1 transcription factors. J Virol 2002;76: 11166-71
21. Nemeroff ME, Barabino SM, Li Y, et al. Influenza virus NS1 protein interacts with the cellular 30 kDa subunit of CPSF and inhibits 3'end formation of cellular pre-mRNAs. Mol Cell 1998;1:991-1000
22. Noah DL, Twu KY, Krug RM. Cellular antiviral responses against influenza A virus are countered at the posttranscriptional level by the viral NS1A protein via its binding to a cellular protein required for the 3' end processing of cellular pre-mRNAS. Virology 2003;307:386-95
23. Talon J, Salvatore M, O'Neill RE, et al. Influenza A and B viruses expressing altered NS1 proteins: A vaccine approach. Proc Natl Acad Sci USA 2000;97:4309-14
24. Burns CC, Shaw J, Campagnoli R, et al. Modulation of poliovirus replicative fitness in HeLa cells by deoptimization of synonymous codon usage in the capsid region. J Virol 2006;80:3259-72
25. Nogales A, Baker SF, Ortiz-Riano E, et al. Influenza A virus attenuation by codon deoptimization of the NS gene for vaccine development. J Virol 2014;88:10525-40
26. Zamarin D, Garcia-Sastre A, Xiao X, et al. Influenza virus PB1-F2 protein induces cell death through mitochondrial ANT3 and VDAC1. PLoS Pathog 2005;1:e4
27. Le Goffic R, Leymarie O, Chevalier C, et al. Transcriptomic analysis of host immune and cell death responses associated with the influenza A virus PB1-F2 protein. PLoS Pathog 2011;7:e1002202
28. McAuley JL, Chipuk JE, Boyd KL, et al. PB1-F2 proteins from H5N1 and 20 century pandemic influenza viruses cause immunopathology. PLoS Pathog 2010;6: e1001014
29. McAuley JL, Hornung F, Boyd KL, et al. Expression of the 1918 influenza A virus PB1-F2 enhances the pathogenesis of viral and secondary bacterial pneumonia. Cell Host Microbe 2007;2:240-9
30. Desmet EA, Bussey KA, Stone R, Takimoto T. Identification of the N-terminal domain of the influenza virus PA responsible for the suppression of host protein synthesis. J Virol 2013;87:3108-18
31. Hu J, Liu X. Crucial role of PA in virus life cycle and host adaptation of influenza A virus. Med Microbiol Immunol 2015;204:137-49
32. Hu J, Mo Y, Wang X, et al. PA-X decreases the pathogenicity of highly pathogenic H5N1 influenza A virus in avian species by inhibiting virus replication and host response. J Virol 2015;89:4126-42
33. Chiou HE, Liu CL, Buttrey MJ, et al. Adverse effects of ribavirin and outcome in severe acute respiratory syndrome: experience in two medical centers. Chest 2005;128:263-72
34. Muller MP, Dresser L, Raboud J, et al. Adverse events associated with high-dose ribavirin: evidence from the Toronto outbreak of severe acute respiratory syndrome. Pharmacotherapy 2007;27: 494-503
35. World Health Organization. Middle east respiratory syndrome coronavirus (MERSCoV). 2015. Available from: www. who. int/ mediacentre/factsheets/mers-cov/en/ Last accessed 21 June 2015]
36. Roberts A, Lamirande EW, Vogel L, et al. Animal models and vaccines for SARS-CoV infection. Virus Res 2008;133:20-32
37. Vogel LN, Roberts A, Paddock CD, et al. Utility of the aged BALB/c mouse model to demonstrate prevention and control strategies for severe acute respiratory syndrome coronavirus (SARS-CoV). Vaccine 2007;25:2173-9
38. Roberts A, Deming D, Paddock CD, et al. A mouse-adapted SARS-coronavirus causes disease and mortality in BALB/c mice. PLoS Pathog 2007;3:e5
39. Agnihothram S, Yount BL Jr, Donaldson EF, et al. A mouse model for Betacoronavirus subgroup 2c using a bat coronavirus strain HKU5 variant. MBio 2014;5:e00047-14
40. Zhao J, Li K, Wohlford-Lenane C, et al. Rapid generation of a mouse model for Middle East respiratory syndrome. Proc Natl Acad Sci USA 2014;111:4970-5
41. Perlman S, Netland J. Coronaviruses post-SARS: update on replication and pathogenesis. Nat Rev Microbiol 2009;7: 439-50
42. Enjuanes L, Dediego ML, Alvarez E, et al. Vaccines to prevent severe acute respiratory syndrome coronavirus-induced disease. Virus Res 2008;133:45-62
43. Knoops K, Barcena M, Limpens RW, et al. Ultrastructural characterization of arterivirus replication structures: reshaping the endoplasmic reticulum to accommodate viral RNA synthesis. J Virol 2012;86: 2474-87
44. Beachboard DC, Anderson-Daniels JM, Denison MR. Mutations across murine hepatitis virus nsp4 alter virus fitness and membrane modifications. J Virol 2015;89: 2080-9
45. Angelini MM, Akhlaghpour M, Neuman BW, Buchmeier MJ. Severe acute respiratory syndrome coronavirus nonstructural proteins 3, 4, and 6 induce double-membrane vesicles. MBio 2013;4
46. Eckerle LD, Lu X, Sperry SM, et al. High fidelity of murine hepatitis virus replication is decreased in nsp14 exoribonuclease mutants. J Virol 2007;81:12135-44
47. Smith EC, Blanc H, Surdel MC, et al. Coronaviruses lacking exoribonuclease activity are susceptible to lethal mutagenesis: evidence for proofreading and potential therapeutics. PLoS Pathog 2013;9:e1003565
48. Smith EC, Denison MR. Implications of altered replication fidelity on the evolution and pathogenesis of coronaviruses. Curr Opin Virol 2012;2:519-24
49. de Haan CA, Masters PS, Shen X, et al. The group-specific murine coronavirus genes are not essential, but their deletion, by reverse genetics, is attenuating in the natural host. Virology 2002;296:177-89
50. DeDiego ML, Nieto-Torres JL, Jimenez-Guardeno JM, et al. Coronavirus virulence genes with main focus on SARS-CoV envelope gene. Virus Res 2014;194:124-37
51. DeDiego ML, Nieto-Torres JL, Jimenez-Guardeno JM, et al. Severe acute respiratory syndrome coronavirus envelope protein regulates cell stress response and apoptosis. PLoS Pathog 2011;7:e1002315
52. Nieto-Torres JL, Dediego ML, Alvarez E, et al. Subcellular location and topology of severe acute respiratory syndrome coronavirus envelope protein. Virology 2011;415:69-82
53. Liu DX, Inglis SC. Association of the infectious bronchitis virus 3c protein with the virion envelope. Virology 1991;185: 911-17
54. Yin XJ, Liu DX, Wang HC, Zhou Y. A study on the mutagenicity of 102 raw pharmaceuticals used in Chinese traditional medicine. Mutat Res 1991;260:73-82
55. Westerbeck JW, Machamer CE. A coronavirus e protein is present in two distinct pools with different effects on assembly and the secretory pathway. J Virol 2015
56. DeDiego ML, Alvarez E, Almazan F, et al. A severe acute respiratory syndrome coronavirus that lacks the E gene is attenuated in vitro and in vivo. J Virol 2007;81:1701-13
57. Dediego ML, Pewe L, Alvarez E, et al. Pathogenicity of severe acute respiratory coronavirus deletion mutants in hACE-2 transgenic mice. Virology 2008;376:379-89
58. Almazan F, DeDiego ML, Sola I, et al. Engineering a replication-competent, propagation-defective Middle East respiratory syndrome coronavirus as a vaccine candidate. MBio 2013;4:e00650-13
59. Ortego J, Escors D, Laude H, Enjuanes L. Generation of a replication-competent, propagation-deficient virus vector based on the transmissible gastroenteritis coronavirus genome. J Virol 2002;76:11518-29
60. Roberts A, Vogel L, Guarner J, et al. Severe acute respiratory syndrome coronavirus infection of golden Syrian hamsters. J Virol 2005;79:503-11
61. Graham RL, Becker MM, Eckerle LD, et al. A live, impaired-fidelity coronavirus vaccine protects in an aged, immunocompromised mouse model of lethal disease. Nat Med 2012;18:1820-6
62. Eckerle LD, Becker MM, Halpin RA, et al. Infidelity of SARS-CoV Nsp14-exonuclease mutant virus replication is revealed by complete genome sequencing. PLoS Pathog 2010;6:e1000896
63. Nair H, Nokes DJ, Gessner BD, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 2010;375:1545-55
64. Hall CB, Weinberg GA, Iwane MK, et al. The burden of respiratory syncytial virus infection in young children. N Engl J Med 2009;360:588-98
65. Kamal-Bahl S, Doshi J, Campbell J. Economic analyses of respiratory syncytial virus immunoprophylaxis in high-risk infants: a systematic review. Arch Pediatr Adolesc Med 2002;156:1034-41
66. Glezen WP, Taber LH, Frank AL, Kasel JA. Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child 1986;140:543-6
67. Kim HW, Leikin SL, Arrobio J, et al. Cell-mediated immunity to respiratory syncytial virus induced by inactivated vaccine or by infection. Pediatr Res 1976;10:75-8
68. Collins PL, Melero JA. Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years. Virus Res 2011;162:80-99
69. Collins PL, Hill MG, Camargo E, et al. Production of infectious human respiratory syncytial virus from cloned cDNA confirms an essential role for the transcription elongation factor from the 5' proximal open reading frame of the M2 mRNA in gene expression and provides a capability for vaccine development. Proc Natl Acad Sci USA 1995;92:11563-7
70. Hotard AL, Shaikh FY, Lee S, et al. A stabilized respiratory syncytial virus reverse genetics system amenable to recombination-mediated mutagenesis. Virology 2012;434:129-36
71. Bitko V, Shulyayeva O, Mazumder B, et al. Nonstructural proteins of respiratory syncytial virus suppress premature apoptosis by an NF-kappaB-dependent, interferon-independent mechanism and facilitate virus growth. J Virol 2007;81: 1786-95
72. Jin H, Cheng X, Traina-Dorge VL, et al. Evaluation of recombinant respiratory syncytial virus gene deletion mutants in African green monkeys for their potential as live attenuated vaccine candidates. Vaccine 2003;21:3647-52
73. Lo MS, Brazas RM, Holtzman MJ. Respiratory syncytial virus nonstructural proteins NS1 and NS2 mediate inhibition of Stat2 expression and alpha/beta interferon responsiveness. J Virol 2005;79:9315-19
74. Spann KM, Tran KC, Chi B, et al. Suppression of the induction of alpha, beta, and lambda interferons by the NS1 and NS2 proteins of human respiratory syncytial virus in human epithelial cells and macrophages [corrected]. J Virol 2004;78: 4363-9
75. Swedan S, Musiyenko A, Barik S. Respiratory syncytial virus nonstructural proteins decrease levels of multiple members of the cellular interferon pathways. J Virol 2009;83:9682-93
76. Whitehead SS, Bukreyev A, Teng MN, et al. Recombinant respiratory syncytial virus bearing a deletion of either the NS2 or SH gene is attenuated in chimpanzees. J Virol 1999;73:3438-42
77. Jin H, Zhou H, Cheng X, et al. Recombinant respiratory syncytial viruses with deletions in the NS1, NS2, SH, and M2-2 genes are attenuated in vitro and in vivo. Virology 2000;273:210-18
78. Meng J, Lee S, Hotard AL, Moore ML. Refining the balance of attenuation and immunogenicity of respiratory syncytial virus by targeted codon deoptimization of virulence genes. MBio 2014;5:e01704-14
79. Collins PL, Mottet G. Membrane orientation and oligomerization of the small hydrophobic protein of human respiratory syncytial virus. J Gen Virol 1993;74(Pt 7): 1445-50
80. Perez M, Garcia-Barreno B, Melero JA, et al. Membrane permeability changes induced in Escherichia coli by the SH protein of human respiratory syncytial virus. Virology 1997;235:342-51
81. Carter SD, Dent KC, Atkins E, et al. Direct visualization of the small hydrophobic protein of human respiratory syncytial virus reveals the structural basis for membrane permeability. FEBS Lett 2010;584:2786-90
82. Fuentes S, Tran KC, Luthra P, et al. Function of the respiratory syncytial virus small hydrophobic protein. J Virol 2007;81: 8361-6
83. Bukreyev A, Whitehead SS, Murphy BR, Collins PL. Recombinant respiratory syncytial virus from which the entire SH gene has been deleted grows efficiently in cell culture and exhibits site-specific attenuation in the respiratory tract of the mouse. J Virol 1997;71:8973-82
84. Whitehead SS, Juhasz K, Firestone CY, et al. Recombinant respiratory syncytial virus (RSV) bearing a set of mutations from cold-passaged RSV is attenuated in chimpanzees. J Virol 1998;72:4467-71
85. Karron RA, Wright PF, Belshe RB, et al. Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants. J Infect Dis 2005;191:1093-104
86. Levine S, Klaiber-Franco R, Paradiso PR. Demonstration that glycoprotein G is the attachment protein of respiratory syncytial virus. J Gen Virol 1987;68(Pt 9):2521-4
87. Feldman SA, Hendry RM, Beeler JA. Identification of a linear heparin binding domain for human respiratory syncytial virus attachment glycoprotein G. J Virol 1999;73:6610-17
88. Olmsted RA, Elango N, Prince GA, et al. Expression of the F glycoprotein of respiratory syncytial virus by a recombinant vaccinia virus: comparison of the individual contributions of the F and G glycoproteins to host immunity. Proc Natl Acad Sci USA 1986;83:7462-6
89. Bukreyev A, Yang L, Fricke J, et al. The secreted form of respiratory syncytial virus G glycoprotein helps the virus evade antibody-mediated restriction of replication by acting as an antigen decoy and through effects on Fc receptor-bearing leukocytes. J Virol 2008;82:12191-204
90. Tripp RA, Jones LP, Haynes LM, et al. CX3C chemokine mimicry by respiratory syncytial virus G glycoprotein. Nat Immunol 2001;2:732-8
91. Polack FP, Irusta PM, Hoffman SJ, et al. The cysteine-rich region of respiratory syncytial virus attachment protein inhibits innate immunity elicited by the virus and endotoxin. Proc Natl Acad Sci USA 2005;102:8996-9001
92. Plattet P, Plemper RK. Envelope protein dynamics in paramyxovirus entry. MBio 2013;4
93. McLellan JS, Ray WC, Peeples ME. Structure and function of respiratory syncytial virus surface glycoproteins. Curr Top Microbiol Immunol 2013;372:83-104
94. Teng MN, Whitehead SS, Collins PL. Contribution of the respiratory syncytial virus G glycoprotein and its secreted and membrane-bound forms to virus replication in vitro and in vivo. Virology 2001;289: 283-96
95. Techaarpornkul S, Collins PL, Peeples ME. Respiratory syncytial virus with the fusion protein as its only viral glycoprotein is less dependent on cellular glycosaminoglycans for attachment than complete virus. Virology 2002;294:296-304
96. Tang RS, Spaete RR, Thompson MW, et al. Development of a PIV-vectored RSV vaccine: preclinical evaluation of safety, toxicity, and enhanced disease and initial clinical testing in healthy adults. Vaccine 2008;26:6373-82
97. Schmidt AC, Wenzke DR, McAuliffe JM, et al. Mucosal immunization of rhesus monkeys against respiratory syncytial virus subgroups A and B and human parainfluenza virus type 3 by using a live cDNA-derived vaccine based on a host range-attenuated bovine parainfluenza virus type 3 vector backbone. J Virol 2002;76: 1089-99
98. Jones B, Zhan X, Mishin V, et al. Human PIV-2 recombinant Sendai virus (rSeV) elicits durable immunity and combines with two additional rSeVs to protect against hPIV-1, hPIV-2, hPIV-3, and RSV. Vaccine 2009;27:1848-57
99. Falsey AR, Walsh EE, Capellan J, et al. Comparison of the safety and immunogenicity of 2 respiratory syncytial virus (rsv) vaccines-nonadjuvanted vaccine or vaccine adjuvanted with alum-given concomitantly with influenza vaccine to high-risk elderly individuals. J Infect Dis 2008;198:1317-26
100. Power UF, Plotnicky H, Blaecke A, Nguyen TN. The immunogenicity, protective efficacy and safety of BBG2Na, a subunit respiratory syncytial virus (RSV) vaccine candidate, against RSV-B. Vaccine 2003;22:168-76
101. Plotnicky H, Siegrist CA, Aubry JP, et al. Enhanced pulmonary immunopathology following neonatal priming with formalin-inactivated respiratory syncytial virus but not with the BBG2NA vaccine candidate. Vaccine 2003;21:2651-60
102. Roush SW, Murphy TV; Vaccine-Preventable Disease Table Working G. Historical comparisons of morbidity and mortality for vaccine-preventable diseases in the United States. JAMA 2007;298:2155-63
103. Katz SL, John F. Enders and measles virus vaccine-a reminiscence. Curr Top Microbiol Immunol 2009;329:3-11
104. Buynak EB, Hilleman MR. Live attenuated mumps virus vaccine Vaccine development. Proc Soc Exp Biol Med 1966;123:768-75
105. Betakova T, Svetlikova D, Gocnik M. Overview of measles and mumps vaccine: origin, present, and future of vaccine production. Acta Virol 2013;57:91-6
106. Haralambieva IH, Ovsyannikova IG, O'Byrne M, et al. A large observational study to concurrently assess persistence of measles specific B-cell and T-cell immunity in individuals following two doses of MMR vaccine. Vaccine 2011;29:4485-91
107. Haralambieva IH, Ovsyannikova IG, Pankratz VS, et al. The genetic basis for interindividual immune response variation to measles vaccine: new understanding and new vaccine approaches. Expert Rev Vaccines 2013;12:57-70
108. Poland GA, Jacobson RM, Thampy AM, et al. Measles reimmunization in children seronegative after initial immunization. JAMA 1997;277:1156-8
109. Pannuti CS, Morello RJ, Moraes JC, et al. Identification of primary and secondary measles vaccine failures by measurement of immunoglobulin G avidity in measles cases during the 1997 Sao Paulo epidemic. Clin Diagn Lab Immunol 2004;11:119-22
110. Pagano JS, Levine RH, Sugg WC, Finger JA. Clinical trial of new attenuated mumps virus vaccine (Jeryl Lynn strain): preliminary report. Prog Immunobiol Stand 1967;3:196-202
111. Weibel RE, Stokes J Jr, Buynak EB, et al. Jeryl Lynn strain live attenuated mumps virus vaccine. Durability of immunity following administration. JAMA 1968;203: 14-18
112. Young ML, Dickstein B, Weibel RE, et al. Experiences with Jeryl Lynn strain live attenuated mumps virus vaccine in a pediatric outpatient clinic. Pediatrics 1967;40:798-803
113. Marin M, Quinlisk P, Shimabukuro T, et al. Mumps vaccination coverage and vaccine effectiveness in a large outbreak among college students-Iowa, 2006. Vaccine 2008;26:3601-7
114. Barskey AE, Glasser JW, LeBaron CW. Mumps resurgences in the United States: A historical perspective on unexpected elements. Vaccine 2009;27:6186-95
115. Poland GA, Jacobson RM. The re-emergence of measles in developed countries: time to develop the next-generation measles vaccines? Vaccine 2012;30:103-4
116. Smits G, Mollema L, Hahne S, et al. Seroprevalence of mumps in The Netherlands: dynamics over a decade with high vaccination coverage and recent outbreaks. PLoS One 2013;8:e58234
117. Mahamud A, Fiebelkorn AP, Nelson G, et al. Economic impact of the 2009-2010 Guam mumps outbreak on the public health sector and affected families. Vaccine 2012;30:6444-8
118. Rima BK, Duprex WP. New concepts in measles virus replication: getting in and out in vivo and modulating the host cell environment. Virus Res 2011;162:47-62
119. Sato H, Masuda M, Kanai M, et al. Measles virus N protein inhibits host translation by binding to eIF3-p40. J Virol 2007;81:11569-76
120. Bhaskar A, Bala J, Varshney A, Yadava P. Expression of measles virus nucleoprotein induces apoptosis and modulates diverse functional proteins in cultured mammalian cells. PLoS One 2011;6:e18765
121. de Vries RD, Stittelaar KJ, Osterhaus AD, de Swart RL. Measles vaccination: new strategies and formulations. Expert Rev Vaccines 2008;7:1215-23
122. Xu P, Chen Z, Phan S, et al. Immunogenicity of novel mumps vaccine candidates generated by genetic modification. J Virol 2014;88:2600-10
123. Xu P, Luthra P, Li Z, et al. The V protein of mumps virus plays a critical role in pathogenesis. J Virol 2012;86:1768-76
124. Xu P, Li Z, Sun D, et al. Rescue of wild-type mumps virus from a strain associated with recent outbreaks helps to define the role of the SH ORF in the pathogenesis of mumps virus. Virology 2011;417:126-36
125. Cheng BY, Ortiz-Riano E, Nogales A, et al. Development of live-attenuated arenavirus vaccines based on codon deoptimization. J Virol 2015;89:3523-33
126. Ni YY, Zhao Z, Opriessnig T, et al. Computer-aided codon-pairs deoptimization of the major envelope GP5 gene attenuates porcine reproductive and respiratory syndrome virus. Virology 2014;450-451: 132-9
127. Aragones L, Guix S, Ribes E, et al. Fine-tuning translation kinetics selection as the driving force of codon usage bias in the hepatitis A virus capsid. PLoS Pathog 2010;6:e1000797
128. Mueller S, Papamichail D, Coleman JR, et al. Reduction of the rate of poliovirus protein synthesis through large-scale codon deoptimization causes attenuation of viral virulence by lowering specific infectivity. J Virol 2006;80:9687-96